At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 5 enrolled
Drug / intervention
ORGN001 (formerly ALXN1101)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A
In Brief
A Phase 3 clinical trial evaluating ORGN001 (formerly ALXN1101) for Molybdenum Cofactor Deficiency, Type A. Completed, enrolled 5 participants across 11 sites in 6 countries.
Detailed Summary
To evaluate the safety and efficacy of ORGN001(formerly ALXN1101) in neonate patients with MoCD Type A
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMolybdenum Cofactor Deficiency, Type A
CountriesIsrael, Norway, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartMay 2016
Primary CompletionSep 2022
Study CompletionOct 2022
TodayJul 2026
First PostedDec 14, 2015
Enrollment StartMay 1, 2016
Primary CompletionSep 1, 2022
Study CompletionOct 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 10.5 years ago
Interventions
ORGN001 (formerly ALXN1101)drug